Norwood Immunology -- Publication in Leading Scientific Journal.

MELBOURNE, Australia -- Norwood Immunology Limited (AIM:NIM) (OTC:NABYF) (ASX:NAL):

Key Points:

--Core research findings published in the Journal of Immunology 

--Data shows that it is possible to reverse the natural immune system aging process

Norwood Immunology Limited (AIM:NIM) (OTC:NABYF) (ASX:NAL), the company focused on the rejuvenation of the immune system, today announces the publication of its core research findings in a leading international peer reviewed journal, The Journal of Immunology.

The publication in The Journal of Immunology, 2005, 175: 2741-2753, was co-authored by Associate Professor Richard Boyd, the Company's Chief Scientific Officer, and Dr. Jayne Sutherland, a post-doctorate fellow working under his supervision at Monash University in Melbourne, Australia.

The publication shows that it is possible to reverse the natural aging process in the immune system in mice and humans, using the normal hormone Leuteinizing Hormone-Releasing Hormone (LHRH) to temporarily inhibit sex steroids. In doing so they were able to revitalize the thymus, the major engine room of the immune system, stimulating it to produce more of the T cells required to maintain good health.

This increased output of new T cells, led to enhanced T cell responses and improved recovery of the immune system following bone marrow transplantation. The loss of sex steroids also increased the level of haemopoietic stem cells in the bone marrow. These cells are important for the bone marrow and thymus to produce between them, all blood cells. It also showed for the first time, that prostate cancer patients who had sex steroids temporarily suppressed as part of their normal therapy, have increased levels of new T cells in their blood.

The immune system deteriorates severely with age and is further destroyed by severe viral infections and common cancer treatments such as chemotherapy and radiotherapy. The ability to overcome these immune system deficiencies potentially provides a new approach to treating a number of indications, in particular cancer. Furthermore, it may also boost the effectiveness of vaccines to cancer and infections.

Richard Williams, CEO of Norwood Immunology, commented: "This is the first of several publications relating to the Company's research that we anticipate this year. Acceptance of this publication further supports the scientific merit and the significance of the Company's research. The international exposure in such a major journal is likely to attract further interest in its potential clinical applications."

For further information on Norwood Immunology, visit www.norwoodimmunology.com.

Background:

Norwood Immunology has licensed its immunology intellectual property to TAP Pharmaceutical Products Inc. for commercialization in the United States, utilizing TAP's GnRH analogue, Lupron Depot(R) (leuprolide acetate for depot suspension). This combined initiative is exploring the use of Lupron Depot in regenerating the thymus gland and in turn "re-booting" the body's immune system, enabling patients to better recover from life-threatening diseases.

TAP Pharmaceutical Products Inc., located in Lake Forest, IL., U.S.A., is a joint venture between Abbott Laboratories, headquartered in Abbott Park, IL., U.S.A., and Takeda Pharmaceutical Company Limited of Osaka, Japan. TAP currently markets Lupron Depot and Prevacid(R) (lansoprazole). For more information about TAP and its products, please visit the company's web site at www.tap.com.